Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 40th JPMorgan Healthcare Conference today with Crinetics. I'm joined by the company's CEO, Scott Struthers, who's going to give a presentation on the business, and then we're going to follow that up with some Q&A. (Operator Instructions)
So with that, let me pass it over to Scott.
Thanks, Jess. Thanks for the invite, and thanks for the opportunity to talk to you and the team and all our investors out there in the virtual world. I'll be flipping through slides and giving slide numbers, which the group can follow along on their own.
And first, just start by referring people to our safe harbor statements since I will be making forward-looking statements.
But if the audience will go to Slide 3, I just wanted to start by saying we had a remarkable year
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |